Study wrapper · #710
Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells.
Editor's note
This is a notable counter-signal study on MOTS-c, the mitochondrial-derived peptide often framed as an exercise-mimetic metabolic regulator. Using adipose-derived mesenchymal stromal cells from people with obesity and lean donors, plus a mouse kidney-stenosis model, researchers reported that exogenous MOTS-c did activate AMPK signaling but paradoxically reduced cell proliferation, increased senescence markers (p16, p21) and TNF-alpha, and, in vivo, failed to improve kidney perfusion, fibrosis or injury, while also blunting the reparative efficacy of lean-donor cells. The message is that metabolic activation did not translate to improved regenerative function and may have worsened senescence and inflammation. It is preclinical (human cells plus mouse model), but a well-constructed cautionary data point against assuming MOTS-c is uniformly beneficial. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
MOTS-c is a small peptide made by our mitochondria that helps regulate metabolism and is sometimes described as mimicking exercise. This study asked whether adding MOTS-c could restore the healing ability of stem-like repair cells taken from the fat tissue of people with obesity, whose cells often work poorly. The researchers treated these human cells with MOTS-c and also tested MOTS-c-primed cells in mice with narrowed kidney arteries. MOTS-c did switch on an energy-sensing pathway (AMPK) as expected. But surprisingly, it also slowed the cells' growth, increased signs of cell aging and inflammation, and in the mice it failed to improve kidney damage, and even reduced the healing power of healthy donor cells. The takeaway is that boosting the metabolic signal did not improve, and may have harmed, the cells' repair ability. This is laboratory and animal research, not a test in patients.